Stay updated with breaking news from சால்ஸ்மேன் குழு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107 Claritas Pharmaceuticals, Inc.April 21, 2021 GMT SAN FRANCISCO and TORONTO, April 21, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into an agreement with CMAX Clinical Research Pty Ltd (“CMAX”) to conduct a randomized, placebo-controlled, single-blind, single ascending dose Phase 1 clinical study to evaluate the pharmacokinetics and safety profile of the Company’s novel, liquid, nitric oxide-releasing drug, R-107. ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH Claritas Pharmaceuticals, Inc.April 14, 2021 GMT SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the “Salzman Group”), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of pulmonary arterial hypertension (“PAH”). The Company expects that definitive agreements will be executed by May 15, 2021. Closing of the transaction is sub ....
Claritas Announces Completion of Canine Toxicology Studies globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Claritas (Formerly Kalytera Therapeutics) Cites Breakthrough Data by Massachusetts General . Claritas Pharmaceuticals, Inc.March 2, 2021 GMT SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas”) today announced that compelling data demonstrating that nitric oxide achieved viral clearance in severe and critical COVID-19 patients validates the potential of the Company’s proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection. Breakthrough Data with Nitric Oxide in COVID-19 ....